BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston. T ...

Matinas BioPharma Hldgs (NYSEMKT:MTNB) just reported results for the first quarter of 2024.Matinas BioPharma Hldgs reported earnings per share of -3 cents. This met the analyst estimate for EPS of -3 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to a ...

财务数据和关键指标变化 - 公司在2024年第一季度未产生收入,相比2023年同期的1.1百万美元收入有所下降 [22] - 2024年第一季度总成本和费用为5.9百万美元,相比2023年同期的6.7百万美元有所下降,主要由于临床开发费用、人员成本和管理费用的减少 [23] - 2024年第一季度净亏损为5.8百万美元,每股0.03美元,与2023年同期的5.5百万美元、每股0.03美元持平 [24] - 截至2024年3月31日,公司现金、现金等价物和可流通证券为8.1百万美元 [24] - 2024年4月,公司通过注册直接融资筹集了1000万美元的资金,预计目前的现金资源足以支持计划运营到2025年第二季度 [24] 各条业务线数据和关键指标变化 - 公司正在推进MAT2203(口服两性霉素B)的合作伙伴关系,目标是在2024年第二季度完成交易 [10][31][32] - MAT2203在同情扩大使用计划中显示出对多种严重和潜在致命的侵袭性真菌感染的安全和有效性,包括被认为比曲霉菌感染更难治疗的黑色真菌感染 [11][12][13] - 公司已成功将多种化疗药物(如多西他赛和米立铂)制成口服脂质纳米囊载体(LNC)制剂,在体内试验中显示出更好的肿瘤靶向性和更低的毒性 [14][15][16] - 公司已成功口服给药小寡核苷酸,在多种炎症性疾病模型中显示出生物活性,正在进一步探索应用 [17][18][19] 各个市场数据和关键指标变化 - 未提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司正专注于为MAT2203寻找合适的开发和商业化合作伙伴,以最大化其在多个地理区域的价值 [10] - 公司正在扩展LNC平台技术在肿瘤学和炎症领域的应用,包括开发口服化疗药物和小寡核苷酸递送系统,以填补重大未满足的医疗需求 [14][16][17][20][27] - 公司认为LNC平台具有成为首选的下一代口服靶向细胞内递送技术的潜力 [20][27] 管理层对经营环境和未来前景的评论 - 管理层对MAT2203作为治疗侵袭性真菌感染的潜在生命改变疗法的前景持乐观态度,并将其推进至III期临床试验作为首要目标 [9][11][13][26] - 管理层对LNC平台在肿瘤学和炎症领域的应用前景感到乐观,认为这可以为公司创造新的价值 [14][16][17][20][27] - 管理层表示公司的现金储备足以支持计划运营到2025年第二季度,为推进LNC平台项目提供了资金支持 [24][42][43] 问答环节重要的提问和回答 问题1 **Scott Henry 提问** 关于MAT2203合作伙伴的时间安排,是否会在5月份或第二季度完成 [31] **Jerome Jabbour 回答** 公司目标是在第二季度完成合作伙伴交易,如果能够提前完成当然更好,但更重要的是确保交易条款能最大化MAT2203的价值 [32] 问题2 **Scott Henry 提问** 关于同情扩大使用计划中侵袭性曲霉菌感染患者的情况 [33] **Theresa Matkovits 回答** 目前有约三分之一的患者为侵袭性曲霉菌感染,完成治疗的患者反应良好 [35][36] 问题3 **Scott Henry 提问** 关于ORALTO III期试验的时间安排,是否需要再与FDA沟通 [37] **Jerome Jabbour 回答** 不需要,公司已经与FDA达成III期试验设计的一致,现在主要是与CRO合作和寻找合作伙伴,目标是在2024年第四季度启动III期试验 [38][39][40]

Exhibit 99.1 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company’s strategy to expand its LNC platform into inflammation and oncology supported by favorable in vivo data in multiple disease models Conference call begins at 4:30 p.m. Eastern ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of ...

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day ...

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer James Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Rei Tan - BTIG Robert LeBoyer - Noble Capital Markets Operator Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently ...

Exhibit 99.1 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of ...